ORX489 / Centessa - LARVOL DELTA

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 (GlobeNewswire) - "Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025: ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders."

Preclinical • Psychiatry